首页> 外文期刊>Molecular pharmaceutics >Further reduction in adenovirus vector-mediated liver transduction without largely affecting transgene expression in target organ by exploiting MicroRNA-mediated regulation and the Cre-loxP recombination system
【24h】

Further reduction in adenovirus vector-mediated liver transduction without largely affecting transgene expression in target organ by exploiting MicroRNA-mediated regulation and the Cre-loxP recombination system

机译:通过利用MicroRNA介导的调节和CRE-LOXP重组系统,进一步降低腺病毒载体介导的肝脏转导,而不大部分地影响靶器官中的转基因表达

获取原文
获取原文并翻译 | 示例
           

摘要

In order to detarget undesirable transduction in the liver by an adenovirus (Ad) vector, we previously demonstrated that insertion of sequences perfectly complementary to liver-specific miR-122a into the 3′-untranslated region (UTR) of transgene specifically reduced the transgene expression in the liver by approximately 100-fold; however, a certain level of residual transgene expression was still found in the liver. In order to further suppress the hepatic transduction, we developed a two-Ad vector system that uses the microRNA (miRNA)-regulated transgene expression system and the Cre-loxP recombination system, i.e., insertion of miR-122a target sequences and loxP sites into the transgene expression cassette and coadministration of a Cre recombinase- expressing Ad vector. In addition, to maintain as much as possible the transgene expression in the spleen, which is the target organ of this study, spleen-specific miR-142-3p target sequences were inserted into the 3′-UTR of the Cre recombinase gene to suppress Cre recombinase expression in the spleen. The spleen is an attractive target for immunotherapy because the spleen plays important roles in the immune system. Coadministration of Ad vector possessing CMV promoter-driven Cre recombinase expression cassette with miR-142-3p target sequences resulted in a further 24-fold reduction in the hepatic transgene expression by the Ad vector containing miR-122a target sequences and loxP sites, compared with coadministration of control Ad vector. On the other hand, there was no significant reduction of transgene expression in the spleen.
机译:为了通过腺病毒(Ad)载体抑制肝脏中的不希望的转导,我们先前证明将与肝脏特异性miR-122a完全互补的序列插入到转基因的3'-未翻译区域(UTR)中特异性降低转基因表达在肝脏中约100倍;然而,在肝脏中仍然存在一定水平的残留转基因表达。为了进一步抑制肝脏转导,我们开发了一种双广告传染媒介系统,它使用微润罗纳(miRNA) - 调节的转基因表达系统和CRE-LOXP重组系统,即插入miR-122a靶序列和Loxp位点CRE重组酶表达广告载体的转基因表达盒和共同分子。另外,为了保持尽可能多的脾脏中的转基因表达,即本研究的靶器官,将脾脏特异性miR-142-3p靶序列插入CRE重组酶基因的3'-UTR中以抑制CRE重组酶在脾脏中的表达。脾脏是免疫疗法有吸引力的靶标,因为脾脏在免疫系统中起重要作用。具有MIR-142-3P靶序列的具有MIR-142-3P靶序列的CMV启动子驱动的CRE重组酶表达盒的共同分子导致含有MIR-122A靶序列和LOXP位点的AD载体的肝转基因表达进一步降低24倍。控制广告传染媒介的共同分析。另一方面,脾脏中没有显着降低转基因表达。

著录项

  • 来源
    《Molecular pharmaceutics》 |2012年第12期|共12页
  • 作者单位

    Laboratory of Biochemistry and Molecular Biology Graduate School of Pharmaceutical Sciences Osaka;

    Laboratory of Biochemistry and Molecular Biology Graduate School of Pharmaceutical Sciences Osaka;

    Laboratory of Biochemistry and Molecular Biology Graduate School of Pharmaceutical Sciences Osaka;

    Laboratory of Biochemistry and Molecular Biology Graduate School of Pharmaceutical Sciences Osaka;

    Laboratory of Biochemistry and Molecular Biology Graduate School of Pharmaceutical Sciences Osaka;

    Laboratory of Stem Cell Regulation National Institute of Biomedical Innovation Osaka Japan;

    Laboratory of Biochemistry and Molecular Biology Graduate School of Pharmaceutical Sciences Osaka;

    Laboratory of Stem Cell Regulation National Institute of Biomedical Innovation Osaka Japan;

    Laboratory of Biochemistry and Molecular Biology Graduate School of Pharmaceutical Sciences Osaka;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

    adenovirus vector; Cre recombinase-loxP system; microRNA; targeted expression;

    机译:腺病毒载体;CRE重组酶 - LOXP系统;MicroRNA;有针对性的表达;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号